A Phase I Study of AL8326 in Advanced Solid Tumor

  • STATUS
    Recruiting
  • End date
    Dec 24, 2023
  • participants needed
    40
  • sponsor
    Advenchen Laboratories Nanjing Ltd.
Send
Updated on 24 May 2021
See if I qualify

Summary

  1. Main purpose Objective to study the tolerance and safety of single and multiple administration of repeated 28-day cycles of AL8326 in patients with advanced solid tumor, observe the dose limiting toxicity (DLT) and maximum tolerated dose (MTD).
  2. Secondary purpose 1) Preliminary analysis of the pharmacokinetic characteristics and efficacy of repeated 28-day cycles of AL8326 tablets in patients with advanced solid tumors; 2) According to the results of phase I tolerance test and pharmacokinetics, appropriate dosage and regimen were recommended for phase II clinical trial;

Description

This is a Phase 1 study to evaluate the safetyand efficacy of 28-day cycles of AL8326 therapy. The study is divided into three parts.

  1. Part I To evaluate the dose limiting toxicity (DLT) and general safety during the first 28-day cycle of Al8326 therapy and to evaluate the MTD. It will include a evaluation of 3 subjects per cohort in a 3+3 design in.
  2. Part II Subject will receive a dose from Part 1 of this study for continuous 28-Day cycles of therapy.
  3. Part III This design adopts 3 + 3 dose de-escalation method for exploration. At the same time, the safety, tolerance and pharmacokinetics were observed.

Details
Condition Advanced Solid Tumors
Treatment AL8326 tablets
Clinical Study IdentifierNCT04890587
SponsorAdvenchen Laboratories Nanjing Ltd.
Last Modified on24 May 2021

Eligibility

 Yes No Not Sure

Inclusion Criteria

Patients with the following advanced solid tumors confirmed by histology or cytology (including but not limited to non-small cell lung cancer, cervical cancer, ovarian cancer, breast cancer, pancreatic cancer, liver cancer, colon cancer, head and neck cancer, prostate cancer, kidney cancer, etc.). Lack of effective standard treatment options; or failure (including disease progression or intolerance) or recurrence after conventional standard treatment
For subject received cytotoxic drugs chemotherapy before, the interval between the end of chemotherapy and the signing of informed consent was at least 4 weeks, and must be recovered from the toxic reaction of previous chemotherapy to 1 grade (except for hair loss)
There must be at least measurable lesions in accordance with RECIST 1.1. If there is only one lesion, the lesion must be confirmed by cytology / histology
Main organ function
Absolute neutrophil count (ANC) 1.5 10 ^ 9 / L (1500 / mm ^ 3), platelet 75 10 ^ 9 / L or hemoglobin 9g / dl
Serum total bilirubin 2 times the upper limit
Serum creatinine 1.5 times the upper limit of normal value or creatinine clearance rate 50ml / min
If there is no liver metastasis, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) 2.5 times of the upper limit, or liver metastasis 5 times of the upper limit
Doppler ultrasound evaluation: left ventricular ejection fraction (LVEF) 50%
According to the judgment of the investigator, the laboratory examination results and clinical abnormalities that will not affect the safety of the subjects and the completion of the trial can be arranged into the group
ECOG (PS) score was 0,1
Life expectancy 12 weeks
Age 18 years old and 70 years old
There was no malabsorption or other gastrointestinal diseases affecting drug absorption
Female: for female patients with fertility, pregnancy test must be conducted before treatment, and contraceptive method approved by medical department must be adopted during treatment and within 3 months after treatment; serum or urine pregnancy test in screening period must be negative; it must be non lactation period; andif a female patient is postmenopausal but has not yet reached the postmenopausal state (the duration of menopause is greater than or equal to 12 consecutive months, and there is no other reason except menopause), and has not received sterilization surgery (removal of ovaries and / or uterus), she is considered to be fertile
Male: during surgical sterilization or treatment and within 3 months after the end of the treatment, the contraceptive measures approved by the doctor were adopted
Ability to understand and sign informed consent

Exclusion Criteria

It is known that it is allergic to drugs with similar chemical structure
Use of drugs or other trial drugs without approval within 30 days before enrollment
The condition of each organ system was as follows
Patients with previous history of central nervous system metastasis or uncontrollable symptoms of brain metastasis, spinal cord compression and cancerous meningitis within 8 weeks after the first administration. For patients with CNS metastasis or spinal cord compression, if the clinical status is stable and does not need hormone therapy, and the interval between the treatment (including radiotherapy or surgery) before entering the group is more than 4 weeks, they can participate in this trial
Grade 2 or above hypertension that cannot be controlled by single drug
Acute myocardial infarction occurred within 6 months
At present, there are arrhythmias (such as long QT syndrome, unmeasurable or 480ms of Bazett's corrected QTC)
NYHA cardiac function grade III or IV
Evidence of severe or uncontrollable systemic disease (e.g., unstable or decompensated respiratory, heart, liver, or kidney disease), as judged by the investigators
Any unstable systemic disease (including active infection, angina pectoris, liver and kidney or metabolic disease, etc.)
Other (primary) malignancies (except for completely cured cervical carcinoma in situ or basal cell carcinoma or squamous cell skin carcinoma) within five years
The presence of clinically detectable third space effusion (such as ascites or pleural effusion) requires immediate drainage. Or after treatment, the effusion is not well controlled and continues to increase
Previous history of definite neurological or mental disorders, such as epilepsy or dementia
The function level of each organ was as follows
The results of urine protein analysis showed that urine protein was + +, and 24-hour urine protein was more than 1.0 g
Coagulation dysfunction: Patients with bleeding tendency (such as active peptic ulcer) or undergoing thrombolytic or anticoagulant therapy; under the premise of prothrombin time international normalized ratio (INR) 1.5, it is allowed to use low-dose warfarin (1mg oral, once a day) or low-dose aspirin (less than 100mg daily) for preventive purposes
Patients with arteriovenous thrombosis events within 6 months, such as cerebrovascular accident (including transient ischemic attack), deep venous thrombosis and pulmonary embolism
The patients who had been enrolled before who had withdrawn from this study
HIV antibody is positive, or the patient has other acquired or congenital immunodeficiency disease, or has a history of organ transplantation
At the same time, they received any other anti-tumor treatment
The researcher thinks that it is not suitable to participate in this study
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note